IBDEI0Q9 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11797,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11797,1,3,0)
 ;;=3^Polyarteritis nodosa
 ;;^UTILITY(U,$J,358.3,11797,1,4,0)
 ;;=4^M30.0
 ;;^UTILITY(U,$J,358.3,11797,2)
 ;;=^5011738
 ;;^UTILITY(U,$J,358.3,11798,0)
 ;;=M31.0^^46^574^5
 ;;^UTILITY(U,$J,358.3,11798,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11798,1,3,0)
 ;;=3^Hypersensitivity angiitis
 ;;^UTILITY(U,$J,358.3,11798,1,4,0)
 ;;=4^M31.0
 ;;^UTILITY(U,$J,358.3,11798,2)
 ;;=^60279
 ;;^UTILITY(U,$J,358.3,11799,0)
 ;;=M31.31^^46^574^23
 ;;^UTILITY(U,$J,358.3,11799,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11799,1,3,0)
 ;;=3^Wegener's granulomatosis w/ renal involvement
 ;;^UTILITY(U,$J,358.3,11799,1,4,0)
 ;;=4^M31.31
 ;;^UTILITY(U,$J,358.3,11799,2)
 ;;=^5011745
 ;;^UTILITY(U,$J,358.3,11800,0)
 ;;=N28.89^^46^574^6
 ;;^UTILITY(U,$J,358.3,11800,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11800,1,3,0)
 ;;=3^Kidney & Ureter Disorders,Oth Specified
 ;;^UTILITY(U,$J,358.3,11800,1,4,0)
 ;;=4^N28.89
 ;;^UTILITY(U,$J,358.3,11800,2)
 ;;=^88007
 ;;^UTILITY(U,$J,358.3,11801,0)
 ;;=E85.4^^46^574^11
 ;;^UTILITY(U,$J,358.3,11801,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11801,1,3,0)
 ;;=3^Organ-limited amyloidosis
 ;;^UTILITY(U,$J,358.3,11801,1,4,0)
 ;;=4^E85.4
 ;;^UTILITY(U,$J,358.3,11801,2)
 ;;=^5003017
 ;;^UTILITY(U,$J,358.3,11802,0)
 ;;=M32.14^^46^574^2
 ;;^UTILITY(U,$J,358.3,11802,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11802,1,3,0)
 ;;=3^Glomerular disease in systemic lupus erythematosus
 ;;^UTILITY(U,$J,358.3,11802,1,4,0)
 ;;=4^M32.14
 ;;^UTILITY(U,$J,358.3,11802,2)
 ;;=^5011757
 ;;^UTILITY(U,$J,358.3,11803,0)
 ;;=M32.15^^46^574^16
 ;;^UTILITY(U,$J,358.3,11803,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11803,1,3,0)
 ;;=3^Tubulo-interstitial neuropathy in SLE
 ;;^UTILITY(U,$J,358.3,11803,1,4,0)
 ;;=4^M32.15
 ;;^UTILITY(U,$J,358.3,11803,2)
 ;;=^5011758
 ;;^UTILITY(U,$J,358.3,11804,0)
 ;;=M34.0^^46^574^13
 ;;^UTILITY(U,$J,358.3,11804,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11804,1,3,0)
 ;;=3^Progressive systemic sclerosis
 ;;^UTILITY(U,$J,358.3,11804,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,11804,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,11805,0)
 ;;=E85.81^^46^574^7
 ;;^UTILITY(U,$J,358.3,11805,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11805,1,3,0)
 ;;=3^Light Chain (AL) Amyloidosis
 ;;^UTILITY(U,$J,358.3,11805,1,4,0)
 ;;=4^E85.81
 ;;^UTILITY(U,$J,358.3,11805,2)
 ;;=^5151302
 ;;^UTILITY(U,$J,358.3,11806,0)
 ;;=E85.82^^46^574^24
 ;;^UTILITY(U,$J,358.3,11806,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11806,1,3,0)
 ;;=3^Wild-Type Transthyretin-Related (ATTR) Amyloidosis
 ;;^UTILITY(U,$J,358.3,11806,1,4,0)
 ;;=4^E85.82
 ;;^UTILITY(U,$J,358.3,11806,2)
 ;;=^5151303
 ;;^UTILITY(U,$J,358.3,11807,0)
 ;;=E85.89^^46^574^1
 ;;^UTILITY(U,$J,358.3,11807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11807,1,3,0)
 ;;=3^Amyloidosis,Other
 ;;^UTILITY(U,$J,358.3,11807,1,4,0)
 ;;=4^E85.89
 ;;^UTILITY(U,$J,358.3,11807,2)
 ;;=^334034
 ;;^UTILITY(U,$J,358.3,11808,0)
 ;;=M31.10^^46^574^15
 ;;^UTILITY(U,$J,358.3,11808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11808,1,3,0)
 ;;=3^Thrombotic Microangiopathy,Unspec
 ;;^UTILITY(U,$J,358.3,11808,1,4,0)
 ;;=4^M31.10
 ;;^UTILITY(U,$J,358.3,11808,2)
 ;;=^5161189
 ;;^UTILITY(U,$J,358.3,11809,0)
 ;;=Z87.442^^46^575^1
 ;;^UTILITY(U,$J,358.3,11809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11809,1,3,0)
 ;;=3^Personal Hx of Urinary Calculi
